Literature DB >> 26604642

N-acetylcysteine modulates angiogenesis and vasodilation in stomach such as DNA damage in blood of portal hypertensive rats.

Francielli Licks1, Renata Minuzzo Hartmann1, Camila Marques1, Elizângela Schemitt1, Josieli Raskopf Colares1, Mariana do Couto Soares1, Juliana Reys1, Camila Fisher1, Juliana da Silva1, Norma Possa Marroni1.   

Abstract

AIM: To evaluate the antioxidant effect of N-acetylcysteine (NAC) on the stomach of rats with portal hypertension.
METHODS: Twenty-four male Wistar rats weighing ± 250 g were divided into four experimental groups (n = 6 each): Sham-operated (SO), SO + NAC, partial portal vein ligation (PPVL), and PPVL + NAC. Treatment with NAC in a dose of 10 mg/kg (i.p.) diluted in 0.6 mL of saline solution was administered daily for 7 d starting 8 d after the surgery. Animals from the PPVL and SO group received saline solution (0.6 mL) for the same period of time as the PPVL + NAC and SO + NAC group. On the 15(th) day the animals were anesthetized and we evaluated portal pressure by cannulating mesenteric artery. After, we removed the stomach for further analysis. We performed immunohistochemical analysis for endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), and nitrotirosine (NTT) proteins in stomach. We also evaluated eNOS and VEGF by Western blot analysis and assessed DNA damage in blood samples by the comet assay.
RESULTS: The portal hypertension group exhibited increases in portal pressure when compared to SO group (29.8 ± 1.8 vs 12.0 ± 0.3 mmHg) (P < 0.001). The same was observed when we compared the eNOS (56.8 ± 3.7 vs 13.46 ± 2.8 pixels) (P < 0.001), VEGF (34.9 ± 4.7 vs 17.46 ± 2.6 pixels) (P < 0.05), and NTT (39.01 ± 4.0 vs 12.77 ± 2.3 pixels) (P < 0.05) expression by immunohistochemistry of the PPVL animals with the SO group. The expression of eNOS (0.39 ± 0.03 vs 0.25 ± 0.03 a.μ) (P < 0.01) and VEGF (0.38 ± 0.04 vs 0.26 ± 0.04 a.μ) (P < 0.01) were also evaluated by Western blot analysis, and we observed an increase of both proteins on PPVL animals. We also evaluated the DNA damage by comet assay, and observed an increase on damage index and damage frequency on those animals. NAC decreased portal pressure values in PPVL + NAC animals (16.46 ± 2 vs 29.8 ± 1.8 mmHg) (P < 0.001) when compared to PPVL. The expression of eNOS (14.60 ± 4.1 vs 56.8 ± 3.7 pixels) (P < 0.001), VEGF (19.53 ± 3.2 vs 34.9 ± 4.7 pixels) (P < 0.05) and NTT (21.84 ± 0.7 vs 39.01 ± 4.0 pixels) (P < 0.05) evaluated by immunohistochemistry were also reduced in PPVL + NAC animals. Also, when evaluated by Western blot eNOS expression (0.32 ± 0.03 vs 0.39 ± 0.03 a.μ) (P < 0.05) and VEGF expression (0.31 ± 0.09 vs 0.38 ± 0.04 a.μ) (P < 0.01). Furthermore, NAC modulated DNA damage in PPVL + NAC animals.
CONCLUSION: In view of these results, we believe NAC is able to protect the stomach from the alterations induced by the PPVL procedure.

Entities:  

Keywords:  Antioxidant; Gastropathy; N-Acetylcysteine; Oxidative stress; Portal hypertension

Mesh:

Substances:

Year:  2015        PMID: 26604642      PMCID: PMC4649118          DOI: 10.3748/wjg.v21.i43.12351

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

Review 1.  The management of portal hypertension: rational basis, available treatments and future options.

Authors:  Jaime Bosch; Annalisa Berzigotti; Juan Carlos Garcia-Pagan; Juan G Abraldes
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

2.  Endothelial nitric oxide synthase membrane targeting. Evidence against involvement of a specific myristate receptor.

Authors:  L Busconi; T Michel
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

Review 3.  Regulation of endothelial nitric oxide synthase: location, location, location.

Authors:  Philip W Shaul
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

4.  Glutamine prevents gastric oxidative stress in an animal model of portal hypertension gastropathy.

Authors:  Camila Marques; José L Mauriz; Douglas Simonetto; Claudio A Marroni; María J Tuñon; Javier González-Gallego; Norma P Marrón
Journal:  Ann Hepatol       Date:  2011 Oct-Dec       Impact factor: 2.400

5.  N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat.

Authors:  B Fernando; R Marley; S Holt; R Anand; D Harry; P Sanderson; R Smith; G Hamilton; K Moore
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

Review 6.  Clinical pharmacology of portal hypertension.

Authors:  Cecilia Miñano; Guadalupe Garcia-Tsao
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

7.  Molecular pathophysiology of portal hypertension.

Authors:  Mercedes Fernandez
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

8.  N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome.

Authors:  Rafael Vercelino; Juliana Tieppo; Alexandre Simões Dias; Cláudio Augusto Marroni; Eduardo Garcia; Luise Meurer; Jaqueline Nascimento Picada; Norma Possa Marroni
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-04       Impact factor: 4.080

9.  Concomitant inhibition of oxidative stress and angiogenesis by chronic hydrogen-rich saline and N-acetylcysteine treatments improves systemic, splanchnic and hepatic hemodynamics of cirrhotic rats.

Authors:  Pei-Chang Lee; Ying-Ying Yang; Chien-Sheng Huang; Shie-Liang Hsieh; Kuei-Chuan Lee; Yun-Cheng Hsieh; Tzung-Yan Lee; Han-Chieh Lin
Journal:  Hepatol Res       Date:  2014-08-06       Impact factor: 4.288

10.  Melatonin prevents oxidative stress and changes in antioxidant enzyme expression and activity in the liver of aging rats.

Authors:  José L Mauriz; Virginia Molpeceres; María V García-Mediavilla; Paquita González; Juan P Barrio; Javier González-Gallego
Journal:  J Pineal Res       Date:  2007-04       Impact factor: 13.007

View more
  3 in total

1.  Synergistic antioxidant and anti-inflammatory action of N-acetylcysteine in portal hypertensive gastropathy in rats.

Authors:  Francielli Licks; Renata Minuzzo Hartmann; Elizângela Schemitt; Josieli Raskopf Colares; Camila Marques; Henrique Fillmann; Norma Possa Marroni
Journal:  Hepatol Forum       Date:  2022-04-26

2.  Effects of N-acetylcysteine and metformin treatment on the stereopathological characteristics of uterus and ovary.

Authors:  Bahare Rafiee; Saied Karbalay-Doust; Seyed Mohammad Bagher Tabei; Negar Azarpira; Sanaz Alaee; Parvin Lohrasbi; Soghra Bahmanpour
Journal:  Eur J Transl Myol       Date:  2022-05-09

3.  Oral N-acetylcysteine decreases IFN-γ production and ameliorates ischemia-reperfusion injury in steatotic livers.

Authors:  Jedson R Liggett; Jiman Kang; Suman Ranjit; Olga Rodriguez; Katrina Loh; Digvijay Patil; Yuki Cui; Anju Duttargi; Sang Nguyen; Britney He; Yichien Lee; Kesha Oza; Brett S Frank; DongHyang Kwon; Heng-Hong Li; Bhaskar Kallakury; Andrew Libby; Moshe Levi; Simon C Robson; Thomas M Fishbein; Wanxing Cui; Chris Albanese; Khalid Khan; Alexander Kroemer
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.